Mutations in the SARS-CoV-2 spike receptor binding domain and their delicate balance between ACE2 affinity and antibody evasion

Abstract

Intensive selection pressure constrains the evolutionary trajectory of SARS-CoV-2 genomes and results in various novel variants with distinct mutation profiles. Point mutations, particularly those within the receptor binding domain (RBD) of SARS-CoV-2 spike (S) protein, lead to the functional alteration in both receptor engagement and monoclonal antibody (mAb) recognition. Here, we review the data of the RBD point mutations possessed by major SARS-CoV-2 variants and discuss their individual effects on ACE2 affinity and immune evasion. Many single amino acid substitutions within RBD epitopes crucial for the antibody evasion capacity may conversely weaken ACE2 binding affinity. However, this weakened effect could be largely compensated by specific epistatic mutations, such as N501Y, thus maintaining the overall ACE2 affinity for the spike protein of all major variants. The predominant direction of SARS-CoV-2 evolution lies neither in promoting ACE2 affinity nor evading mAb neutralization but in maintaining a delicate balance between these two dimensions. Together, this review interprets how RBD mutations efficiently resist antibody neutralization and meanwhile how the affinity between ACE2 and spike protein is maintained, emphasizing the significance of comprehensive assessment of spike mutations.

Keywords

SARS-CoV-2 / RBD mutation / antibody evasion / ACE2 affinity / variant of concern / viral evolution

References

[1] Addetia A, Piccoli L, Case JB et al. Neutralization, effector function and immune imprinting of Omicron variants. Nature 2023;621:592–601.

[2] Alcantara MC, Higuchi Y, Kirita Y et al. Deep mutational scanning to predict escape from bebtelovimab in SARS-CoV-2 Omicron subvariants. Vaccines (Basel) 2023;11:711.

[3] Andreano E, Piccini G, Licastro D et al. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. Proc Natl Acad Sci USA 2021;118:e2103154118.

[4] Barton MI, MacGowan SA, Kutuzov MA et al. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics. Elife 2021;10:e70658.

[5] Bouhaddou M, Reuschl AK, Polacco BJ et al. SARS-CoV-2 variants evolve convergent strategies to remodel the host response. Cell 2023;186:4597–4614.e26.

[6] Bruel T, Vrignaud LL, Porrot F et al. Antiviral activities of sotrovimab against BQ.1.1 and XBB.1.5 in sera of treated patients. medRxiv 2023.

[7] Callaway E. COVID ‘variant soup’ is making winter surges hard to predict. Nature 2022;611:213–214.

[8] Cao Y, Song W, Wang L et al. Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75. Cell Host Microbe 2022a;30:1527–1539.e5.e1525.

[9] Cao Y, Wang J, Jian F et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 2022b;602:657–663.

[10] Cao Y, Yisimayi A, Jian F et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 2022c;608:593–602.

[11] Cao Y, Jian F, Wang J et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature 2023;614:521–529.

[12] Carabelli AM, Peacock TP, Thorne LG et al. COVID-19 Genomics UK Consortium. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol 2023;21:162–177.

[13] Chakraborty S. E484K and N501Y SARS-CoV 2 spike mutants Increase ACE2 recognition but reduce affinity for neutralizing antibody. Int Immunopharmacol 2022;102:108424.

[14] Chen RE, Zhang X, Case JB et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med 2021;27:717–726.

[15] Chen Y, Zhao X, Zhou H et al. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat Rev Immunol 2023;23:189–199.

[16] Chi X, Yan R, Zhang J et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science 2020;369:650–655.

[17] Cox M, Peacock TP, Harvey WT et al. COVID-19 Genomics UK (COG-UK) Consortium. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nat Rev Microbiol 2023;21:112–124.

[18] Cui Z, Liu P, Wang N et al. Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron. Cell 2022;185:860–871.e13.

[19] Dadonaite B, Crawford KHD, Radford CE et al. A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike. Cell 2023;186:1263–1278.e20.

[20] Dejnirattisai W, Zhou D, Supasa P et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell 2021;184:2939–2954.e9.

[21] Dejnirattisai W, Huo J, Zhou D et al. OPTIC Consortium. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell 2022;185:467–484.e15.

[22] Driouich JS, Bernadin O, Touret F et al. Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model. Antiviral Res 2023;215:105638.

[23] Duffy S, Shackelton LA, Holmes EC. Rates of evolutionary change in viruses: patterns and determinants. Nat Rev Genet 2008;9:267–276.

[24] Dyer O. Covid-19: Infections climb globally as EG.5 variant gains ground. Bmj 2023;382:1900.

[25] Fan Y, Li X, Zhang L et al. SARS-CoV-2 Omicron variant: recent progress and future perspectives. Signal Transduct Target Ther 2022;7:141.

[26] Faraone JN, Qu P, Goodarzi N et al. Immune evasion and membrane fusion of SARS-CoV-2 XBB Subvariants EG.5.1 and XBB.2.3. Emerg Microbes Infect 2023;12:2–13.

[27] Focosi D, McConnell S, Casadevall A et al. Monoclonal antibody therapies against SARS-CoV-2. Lancet Infect Dis 2022;22:e311–e326.

[28] Focosi D, Quiroga R, McConnell S et al. Convergent evolution in SARS-CoV-2 spike creates a variant soup from which new COVID-19 waves emerge. Int J Mol Sci 2023;24:2264.

[29] Frank F, Keen MM, Rao A et al. Deep mutational scanning identifies SARS-CoV-2 Nucleocapsid escape mutations of currently available rapid antigen tests. Cell 2022;185:3603–3616.e13.

[30] Gobeil SM, Janowska K, McDowell S et al. D614G mutation Alters SARS-CoV-2 spike conformation and enhances protease cleavage at the S1/S2 junction. Cell Rep 2021;34:108630.

[31] Greaney AJ, Loes AN, Crawford KHD et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe 2021a;29:463–476.e6.

[32] Greaney AJ, Starr TN, Barnes CO et al. Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nat Commun 2021b;12:4196.

[33] Greaney AJ, Starr TN, Gilchuk P et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe 2021c;29:44–57.e9.

[34] Greaney AJ, Starr TN, Bloom JD. An antibody-escape estimator for mutations to the SARS-CoV-2 receptor-binding domain. Virus Evol 2022;8:veac021.

[35] Gupta D, Sharma P, Singh M et al. Structural and functional insights into the spike protein mutations of emerging SARS-CoV-2 variants. Cell Mol Life Sci 2021;78:7967–7989.

[36] Han P, Li L, Liu S et al. Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2. Cell 2022;185:630–640.e10.

[37] Hastie KM, Li H, Bedinger D et al. CoVIC-DB team1. Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: a global consortium study. Science 2021;374:472–478.

[38] He Q, Wu L, Xu Z et al. An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB. Cell Rep Med 2023;4:100991.

[39] Hoffmann M, Arora P, Groß R et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 2021;184:2384–2393.e12.e2312.

[40] Huo J, Dijokaite-Guraliuc A, Liu C et al. OPTIC consortium. A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75. Cell Rep 2023;42:111903.

[41] Iketani S, Mohri H, Culbertson B et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature 2023;613:558–564.

[42] Jackson CB, Farzan M, Chen B et al. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol 2022;23:3–20.

[43] Javanmardi K, Chou CW, Terrace CI et al. Rapid characterization of spike variants via mammalian cell surface display. Mol Cell 2021;81:5099–5111.e8.

[44] Javanmardi K, Segall-Shapiro TH, Chou CW et al. Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein. Cell Host Microbe 2022;30:12421254.e6.e1246.

[45] Jian F, Yu Y, Song W et al. Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants. Lancet Infect Dis 2022;22:1535–1537.

[46] Kabinger F, Stiller C, Schmitzová J et al. Mechanism of molnupiravir- induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol 2021;28:740–746.

[47] Kaku Y, Kosugi Y, Uriu K et al. Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against omicron subvariants including EG.5. Lancet Infect Dis 2023;23:e395–e396.

[48] Ke Z, Oton J, Qu K et al. Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature 2020;588:498–502.

[49] Kemp SA, Collier DA, Datir RP et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature 2021;592:277–282.

[50] Knezevic I, Mattiuzzo G, Page M et al. WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community. Lancet Microbe 2022;3:e235–e240.

[51] Korber B, Fischer WM, Gnanakaran S et al. Sheffield COVID-19 Genomics Group. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 2020;182:812–827.e19.e819.

[52] Kumar V, Singh J, Hasnain SE et al. Possible link between higher transmissibility of alpha, kappa and delta variants of SARS-CoV-2 and increased structural stability of its spike protein and hACE2 affinity. Int J Mol Sci 2021;22:9131.

[53] Kumar S, Thambiraja TS, Karuppanan K et al. Omicron and Delta variant of SARS-CoV-2: a comparative computational study of spike protein. J Med Virol 2022;94:1641–1649.

[54] Kumaraswamy S, Tobias R. Label-free kinetic analysis of an antibody-antigen interaction using biolayer interferometry. Methods Mol Biol 2015;1278:165–182.

[55] Li L, Liao H, Meng Y et al. Structural basis of human ACE2 higher binding affinity to currently circulating Omicron SARS-CoV-2 sub-variants BA.2 and BA.1.1. Cell 2022;185:2952–2960.e10.e2910.

[56] Liu C, Ginn HM, Dejnirattisai W et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 2021;184:4220–4236.e4213.

[57] Liu Y, Liu J, Plante KS et al. The N501Y spike substitution enhances SARS-CoV-2 infection and transmission. Nature 2022;602:294–299.

[58] Ma W, Fu H, Jian F et al. Immune evasion and ACE2 binding affinity contribute to SARS-CoV-2 evolution. Nat Ecol Evol 2023;7:1457–1466.

[59] Mannar D, Saville JW, Zhu X et al. Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding. Cell Rep 2021;37:110156.

[60] Mannar D, Saville JW, Zhu X et al. SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex. Science 2022;375:760–764.

[61] Martin DP, Weaver S, Tegally H et al. NGS-SA. The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages. Cell 2021;184:5189e5187–515200.e7.

[62] McCallum M, Czudnochowski N, Rosen LE et al. Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. Science 2022;375:864–868.

[63] McGrath ME, Xue Y, Dillen C et al. SARS-CoV-2 variant spike and accessory gene mutations alter pathogenesis. Proc Natl Acad Sci USA 2022;119:e2204717119.

[64] Meng B, Abdullahi A, Ferreira I et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature 2022;603:706–714.

[65] Moeller NH, Shi K, Demir O et al. Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN. Proc Natl Acad Sci USA 2022;119:e2106379119.

[66] Motozono C, Toyoda M, Zahradnik J et al. Genotype to Phenotype Japan (G2P-Japan) Consortium. SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. Cell Host Microbe 2021;29:1124–1136.e11.e1111.

[67] Moulana A, Dupic T, Phillips AM et al. Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1. Nat Commun 2022;13:7011.

[68] Muruato AE, Fontes-Garfias CR, Ren P et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat Commun 2020;11:4059.

[69] Nie J, Li Q, Wu J et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat Protoc 2020;15:3699–3715.

[70] Ozono S, Zhang Y, Ode H et al. SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity. Nat Commun 2021;12:848.

[71] Park YJ, Pinto D, Walls AC et al. Imprinted antibody responses against SARS-CoV-2 Omicron sublineages. Science 2022;378:619–627.

[72] Piliarik M, Vaisocherová H, Homola J. Surface plasmon resonance biosensing. Methods Mol Biol 2009;503:65–88.

[73] Planas D, Bruel T, Staropoli I et al. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies. Nat Commun 2023;14:824.

[74] Plante JA, Liu Y, Liu J et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature 2021;592:116–121.

[75] Qu P, Evans JP, Faraone JN et al. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. Cell Host Microbe 2023a;31:9–17.e3.e13.

[76] Qu P, Faraone JN, Evans JP et al. Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants. Cell Rep 2023b;42:112443.

[77] Qu P, Xu K, Faraone JN et al. Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 omicron BA.2.86 and FLip variants. bioRxiv 2023c.

[78] Ramanathan M, Ferguson ID, Miao W et al. SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity. Lancet Infect Dis 2021;21:1070.

[79] Ray D, Le L, Andricioaei I. Distant residues modulate conformational opening in SARS-CoV-2 spike protein. Proc Natl Acad Sci USA 2021;118:e2100943118.

[80] Riddell AC, Cutino-Moguel T. The origins of new SARS-COV-2 variants in immunocompromised individuals. Curr Opin HIV AIDS 2023;18:148–156.

[81] Riepler L, Rössler A, Falch A et al. Comparison of four SARS-CoV-2 neutralization assays. Vaccines (Basel) 2020;9:13.

[82] Robson F, Khan KS, Le TK et al. Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting. Mol Cell 2020;79:710–727.

[83] Rochman ND, Koonin EV. Learn from the past to predict viral pandemics. Nature 2023;622:700–702.

[84] Saito A, Irie T, Suzuki R et al. Genotype to Phenotype Japan (G2P-Japan) Consortium. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature 2022;602:300–306.

[85] Scarpa F, Pascarella S, Ciccozzi A et al. Genetic and structural analyses reveal the low potential of the SARS-CoV-2 EG.5 variant. J Med Virol 2023;95:e29075.

[86] Schmidt F, Weisblum Y, Muecksch F et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med 2020;217:e20201181.

[87] Scialo F, Daniele A, Amato F et al. ACE2: the major cell entry receptor for SARS-CoV-2. Lung 2020;198:867–877.

[88] Shang J, Ye G, Shi K et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 2020;581:221–224.

[89] Sheward DJ, Kim C, Fischbach J et al. Evasion of neutralising antibodies by omicron sublineage BA.2.75. Lancet Infect Dis 2022;22:1421–1422.

[90] Shrestha LB, Foster C, Rawlinson W et al. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: implications for immune escape and transmission. Rev Med Virol 2022;32:e2381.

[91] Shu Y, McCauley J. GISAID: global initiative on sharing all influenza data—from vision to reality. Euro Surveill 2017;22:30494.

[92] Shuai H, Chan JF, Hu B et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature 2022;603:693–699.

[93] Starr TN, Thornton JW. Epistasis in protein evolution. Protein Sci 2016;25:1204–1218.

[94] Starr TN, Greaney AJ, Hilton SK et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell 2020;182:1295–1310.e20e1220.

[95] Starr TN, Greaney AJ, Hannon WW et al. Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution. Science 2022a;377:420–424.

[96] Starr TN, Greaney AJ, Stewart CM et al. Deep mutational scans for ACE2 binding, RBD expression, and antibody escape in the SARS-CoV-2 Omicron BA.1 and BA.2 receptor-binding domains. PLoS Pathog 2022b;18:e1010951.

[97] Starr TN, Zepeda SK, Walls AC et al. ACE2 binding is an ancestral and evolvable trait of sarbecoviruses. Nature 2022c;603:913–918.

[98] Supasa P, Zhou D, Dejnirattisai W et al. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell 2021;184:2201–2211.e2207.

[99] Tamura T, Ito J, Uriu K et al. Genotype to Phenotype Japan (G2P-Japan) Consortium. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. Nat Commun 2023a;14:2800.

[100] Tamura T, Ito J, Uriu K et al. Genotype to Phenotype Japan (G2P-Japan) Consortium. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. Nat Commun 2023b;14:2800.

[101] Tan TJC, Mou Z, Lei R et al. High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spike. Nat Commun 2023;14:2003.

[102] Taylor AL, Starr TN. Deep mutational scans of XBB.1.5 and BQ.1.1 reveal ongoing epistatic drift during SARS-CoV-2 evolution. bioRxiv 2023;19:e1011901.

[103] Telenti A, Arvin A, Corey L et al. After the pandemic: perspectives on the future trajectory of COVID-19. Nature 2021;596:495–504.

[104] Thadani NN, Gurev S, Notin P et al. Learning from prepandemic data to forecast viral escape. Nature 2023;622:818–825.

[105] Thorne LG, Bouhaddou M, Reuschl AK et al. Evolution of enhanced innate immune evasion by SARS-CoV-2. Nature 2022;602:487–495.

[106] Tian D, Sun Y, Zhou J et al. The global epidemic of SARS-CoV-2 variants and their mutational immune escape. J Med Virol 2022;94:847–857.

[107] Tregoning JS, Flight KE, Higham SL et al. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol 2021;21:626–636.

[108] Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A et al. OPTIC Consortium. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell 2022;185:2422–2433.e13.e2413.

[109] Uriu K, Ito J, Zahradnik J et al. Genotype to Phenotype Japan (G2P-Japan) Consortium. Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant. Lancet Infect Dis 2023;23:280–281.

[110] Walls AC, Park YJ, Tortorici MA et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020;181:281–292.e6.e286.

[111] Wang P, Nair MS, Liu L et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 2021;593:130–135.

[112] Wang K, Jia Z, Bao L et al. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants. Nature 2022;603:919–925.

[113] Wang Q, Guo Y, Zhang RM et al. Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6. Lancet Infect Dis 2023a;23:e397–e398.

[114] Wang Q, Iketani S, Li Z et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell 2023b;186:279–286.e8.e278.

[115] Westendorf K, Žentelis S, Wang L et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep 2022;39:110812.

[116] Wilkinson E, Giovanetti M, Tegally H et al. A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa. Science 2021;374:423–431.

[117] Wrapp D, Wang N, Corbett KS et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020;367:1260–1263.

[118] Xu K, Gao P, Liu S et al. Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. Cell 2022;185:2265–2278.e2214.

[119] Xu Y, Liu T, Li Y et al. Transmission of SARS-CoV-2 Omicron variant under a dynamic clearance strategy in Shandong, China. Microbiol Spectr 2023;11:e0463222.

[120] Yan R, Zhang Y, Li Y et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020;367:1444–1448.

[121] Yang K, Wang C, White KI et al. Structural conservation among variants of the SARS-CoV-2 spike postfusion bundle. Proc Natl Acad Sci USA 2022;119:e2119467119.

[122] Yin W, Xu Y, Xu P et al. Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody. Science 2022;375:1048–1053.

[123] Yu TC, Thornton ZT, Hannon WW et al. A biophysical model of viral escape from polyclonal antibodies. Virus Evol 2022;8:veac110.

[124] Yuan M, Huang D, Lee CD et al. Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. Science 2021;373:818–823.

[125] Yue C, Song W, Wang L et al. ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5. Lancet Infect Dis 2023;23:278–280.

[126] Zhang L, Jackson CB, Mou H et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun 2020;11:6013.

[127] Zhang J, Xiao T, Cai Y et al. Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant. Science 2021a;374:1353–1360.

[128] Zhang Q, Xiang R, Huo S et al. Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Signal Transduct Target Ther 2021b;6:233.

[129] Zhang W, Shi K, Geng Q et al. Structural basis for mouse receptor recognition by SARS-CoV-2 omicron variant. Proc Natl Acad Sci USA 2022;119:e2206509119.

[130] Zhang L, Kempf A, Nehlmeier I et al. Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3. Lancet Infect Dis 2023;23:e391–e392.

[131] Zhao Z, Xie Y, Bai B et al. Structural basis for receptor binding and broader interspecies receptor recognition of currently circulating Omicron sub-variants. Nat Commun 2023;14:4405.

[132] Zhou D, Dejnirattisai W, Supasa P et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell 2021;184:2348–2361.e2346.

[133] Zhou T, Wang L, Misasi J et al. Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529. Science 2022;376:eabn8897.

RIGHTS & PERMISSIONS

2024 The Author(s) 2024. Published by Oxford University Press on behalf of Higher Education Press.